Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00557193 · OUTCOME

Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2024-07-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
qPCR fold expression ratio
Interval / dispersion
Standard Deviation
Time frame
At relapse (up to 3 years)

What was measured

Described via means and standard deviations in available Arm C relapse samples

Analysis population: Arm C Dose Level 2 patients who relapsed and had data collected.

Groups in this outcome

Arm C (Safety/Efficacy Dose Level 2)

Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm C (Safety/Efficacy Dose Level 2)7

Reported measurements

Source class 1
Values in qPCR fold expression ratio · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Arm C (Safety/Efficacy Dose Level 2)5.734.56Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        4.56
        value
        5.73
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Described via means and standard deviations in available Arm C relapse samples
dispersion Type
Standard Deviation
groups
  1. description
    Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)
    id
    OG000
    title
    Arm C (Safety/Efficacy Dose Level 2)
param Type
MEAN
population Description
Arm C Dose Level 2 patients who relapsed and had data collected.
reporting Status
POSTED
time Frame
At relapse (up to 3 years)
title
Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
type
SECONDARY
unit Of Measure
qPCR fold expression ratio

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice